Results 111 to 120 of about 1,951,078 (347)
Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV Infection [PDF]
Maaike E. Ressing +6 more
openalex +1 more source
Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells
Justin C. Boucher +10 more
openalex +2 more sources
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Benign tumors broaden the field of application for immunotherapy
Immunotherapy has shown significant potential for treating malignancies. Not yet widely considered is the opportunity to employ immunotherapy for the treatment of benign tumors.
Mohamed A. Youssef +5 more
doaj +1 more source
The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method [PDF]
Alison Clargo +18 more
openalex +1 more source
Alternative tumour-specific antigens
Christof C. Smith +5 more
semanticscholar +1 more source
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
Nabil Ahmed +32 more
openalex +2 more sources

